Bifogade filer
20260303_Isofol_PM_Upcoming events_ISO-586, r2
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
GOTHENBURG, Sweden, March 3, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate in Life Science Day on March 4 as well as Stora Aktiedagen on March 10. The presentations are broadcast online and will be available for on-demand viewing afterwards.
The information in the press release is intended for investors.
Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, conducted at the German University Hospital Charité. The drug candidate has the potential to fill a known treatment gap in cancer care.
Life Science Day
On March 4, the Life Science Day will be held in Gothenburg for the tenth time. The day opens with a keynote by Leif Johansson, former Chairman of the Board at AstraZeneca. Isofol will be presented by CEO Petter Segelman Lindqvist at 11:45 a.m. CET.
Life Science Day is organized by Finwire and Företagsfinansiering Fyrstad. The event brings together Swedish companies to be presented to investors, shareholders, researchers, and other stakeholders interested in developments within the life science sector. The presentation can be viewed live at www.lifesciencedagen.se.
Stora Aktiedagarna
On March 10-11, the Swedish Shareholders’ Association (Aktiespararna) is hosting the investor event Stora Aktiedagarna. Isofol is presented by CEO Petter Segelman Lindqvist at 4:25 p.m. CET on Tuesday, March 10. The event will be broadcast online via this link.
These and previous events can be viewed retrospectively on Isofol's website, www.isofolmedical.com.
Colorectal cancer is the third most common form of cancer globally, and the second most common cause of cancer-related death, according to the World Health Organization (WHO). The need for new treatments in the field is thus very high.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: [email protected]
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on March 3, 2026.
About Isofol
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com